Genentech's Susvimo, formerly PDS with ranibizumab, receives US FDA approvalOctober 26th 2021
Susvimo, formerly called the Port Delivery System with ranibizumab, is a first-of-its-kind therapeutic approach for wet AMD and may help people with the disease maintain their vision with as few as two treatments per year.
World Sight Day 2021: How the eye care industry is celebrating #LoveYourEyesOctober 14th 2021
As the world comes together to shine a global spotlight on blindness and vision impairment on World Sight Day, several global organizations and companies are stepping up to increase awareness of eye health, including the importance of regular examinations by an ophthalmologist or optometrist.
Gene therapy helps patient with retinitis pigmentosa achieve partial visionMay 26th 2021
An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.
Measuring visual fields with cloud-based AI platformMay 7th 2021
Dr Mohamed Abou Shousha and Dr Richard Parrish II discuss their ARVO 2021 presentation regarding a study analyzing visual field measurements using the Heru Visual Field Multi-platform application downloaded on two different commercially available augmented reality devices.
Clinical results analyze dexamethasone implant effect on macular thicknessMay 5th 2021
Dr. Daniel F. Kiernan discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
Targeting neurodegenerative diseases using risuteganibMay 3rd 2021
Dr Glenn J. Jaffe discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.
Analysis of an investigational ophthalmic solution for treating presbyopia-related symptomsDecember 13th 2020
Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.
Evaluating long-term safety for micro-bypass implant + phaco in PXGDecember 12th 2020
Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.
Controlling postop pain, inflammation in cataract patients: drug delivery vs dropsDecember 10th 2020
John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.